Dr. Reddy's Laboratories Ltd. Announce Settlement of Clarinex(R) (Desloratadine) ANDA Patent litigation With Schering Corporation And Sepracor, Inc.

HYDERABAD, India--(BUSINESS WIRE)--Dr. Reddy's Laboratories today announced that it has entered into agreements with Schering and Sepracor which will allow Dr. Reddy’s to manufacture and market generic versions of the CLARINEX-D®-12 Hour and CLARINEX-D® -24 Hour products, with six months marketing exclusivity, and the CLARINEX® REDITABS® product, with six months marketing co-exclusivity, starting in 2012. Dr. Reddy’s will also market a generic version of the CLARINEX® 5 milligram tablet six months after the launch of the first generic version of that product.